Nerves as novel actors in the tumor microenvironment: the role of exosomes in ovarian cancer tumor innervation Although advances in surgery and chemotherapy for ovarian cancer have improved survival, most women with ovarian cancer will experience recurrence of their disease. Unfortunately, recurrent ovarian cancers respond poorly to chemotherapy and are incurable, highlighting the need for […]
Read More
T. Rinda Soong, MD, PhDUniversity of Pittsburgh2020 Scientific Scholar Award Early Serous Tubal Proliferations as Alternate Precursors of High-Grade Serous Carcinoma Identifying the origins of high grade serous ovarian cancer can help us understand how to prevent this disease or detect it at earlier, more treatable stages. Precancerous changes in fallopian tube tissue known as […]
Read More
Mary Zhang, PhDUniversity of South Florida Role of HDAC6 and its novel substrate cortactin in ovarian cancer cell motility HDACs are a group of enzymes that regulate cell growth and migration, and hence are likely involved with the metastases of ovarian cancer. This study will examine the role between these enzymes and the molecular events […]
Read More
Keren Levanon, MD, PhDDana-Farber Cancer Institute The Fallopian Tube as field of origin of ovarian serous carcinoma Research on ovarian carcinogenesis has traditionally focused on the ovarian surface epithelium as the fields of origin. More recently, the secretory cell of the fallopian tube has emerged as an alternate cell-of-origin for ovarian and pelvic serous carcinomas, […]
Read More
Christina Annunziata, MD, PhDNational Cancer Institute Characterization of NF-kB signaling as a therapeutic target in ovarian cancer The NF-kB family of transcription factors has been implicated in the increase of ovarian cancer cell lines, but the significance and the mechanism of signaling is unknown. Initial experiments identified a subset of ovarian cancer cell lines that […]
Read More
Shailendra Giri, PhDMayo Clinic S-nitrosylation mediated inactiviation of TSG in ovarian cancer Chronic inflammation has become a well-accepted risk factor for epithelial-derived malignancies, including ovarian cancer. But how inflammation contributes to the process of carcinogenesis is a grey area. If successful, Dr. Giri’s study will elucidate the possible novel regulation of chemical inactivation of LKB1-AMPK […]
Read More
Masafumi Toyoshima, MD, PhDFred Hutchinson Cancer Research Center Identification of Targeted Therapies for MYC-Amplified Ovarian Cancer By Functional Genomics The main goal of Dr. Toyoshima’s research is to investigate whether MYC synthetic lethal genes can be therapeutic targets for ovarian cancer in women whose MYC gene is amplified. Using a siRNA screening strategy this study […]
Read More
Ramandeep Rattan, PhDMayo Clinic TCEAL7, a novel regulator of NFkB-IL-6/STAT3 pathway in ovarian cancer The causes of ovarian cancer are not well understood because of the complexity and the lack of understanding of the various genetic alterations in the development of ovarian cancer and its progression to chemoresistant disease. Dr. Rattan’s study is poised to […]
Read More
Brigitte Thériault, PhDOntario Cancer Institute Modulation of KIF14 overexpression in ovarian cancer Dr. Thériault’s lab had previously discovered that the gene KIF14 is present in high amounts in the majority of ovarian cancers, and that patients with high KIF14 have much worse survival than patients with low KIF14. KIF14 is normally found in cells that […]
Read More
Pradeep Chaluvally Raghavan, PhDM.D. Anderson Cancer Center Unraveling the oncogenic effects of amplified miRNAs in High Grade Serous Epithelial Ovarian Cancer Cancer cells are abnormal partly by having increased copies of certain genes (DNA copy number aberrations), which is an important hallmark of high-grade serous ovarian cancer. Non-protein coding genes such as microRNAs have recently […]
Read More